Acadia Pharmaceuticals (ACAD) Current Leases (2011 - 2012)
Acadia Pharmaceuticals' quarterly Current Leases came in at $3000.0 in Q3 2012, down 76.92% quarter-over-quarter from $13000.0 in Q2 2012.
Acadia Pharmaceuticals has reported Current Leases for 2 years, with the latest figure at $3000.0 in Q3 2012.
- For the quarter ending Q3 2012, Current Leases changed N/A year-over-year to $3000.0; the trailing twelve-month figure through Sep 2012 stood at $3000.0 (changed N/A YoY), and the FY2011 full-year result was $32000.0, changed N/A from the prior year.
- Current Leases for Q3 2012 stood at $3000.0, down from $13000.0 in the prior quarter.
- The five-year high for Current Leases was $32000.0 in Q4 2011, with the low at $3000.0 in Q3 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 45.66 Mn |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | 3,000.00 |
| Jun 30, 2012 | 13,000.00 |
| Dec 31, 2011 | 32,000.00 |